BACKGROUND: Many childhood malignancies including sarcomas, neuroblastoma, and Wilms tumor show the presence of both, active, type-1-insulin-like growth factor receptor (IGF-1R), and the autocrine production of its ligands IGF-1/IGF-2. IMC-A12 is a fully human IgG1 antibody that prevents ligand binding to the IGF-1R. PROCEDURES: IMC-A12 was evaluated against the 23 cell lines of the Pediatric Preclinical Testing Program (PPTP) in vitro panel using 96 hr exposure at concentrations ranging from 0.01 nM to 0.1 microM. IMC-A12 was tested in vivo at a dose of 1 mg/mouse administered intraperitoneally twice weekly for 6 weeks. RESULTS: In vitro, IMC-A12-induced T/C values <50% in only three cell lines, a rhabdomyosarcoma cell line (Rh41) and two Ewing sarcoma cell lines (TC-71 and CHLA-9). In vivo, IMC-A12 induced significant differences in EFS distribution compared to control in 24 of 34 (71%) evaluable solid tumor xenografts. Using the PPTP "time to event" activity measure, IMC-A12 induced intermediate (n = 13) or high (n = 1) activity in 33 xenografts evaluable for this activity measure, including 6 of 6 rhabdomyosarcoma xenografts, 3 of 5 osteosarcoma xenografts, 2 of 5 neuroblastoma xenografts, and 1 of 5 Ewing sarcoma xenografts. The only objective response observed was observed in a rhabdomyosarcoma xenograft (Rh28) that achieved a maintained complete response. CONCLUSIONS: IMC-A12 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression. IMC-A12 showed its greatest activity in vivo against the PPTP's rhabdomyosarcoma xenografts. Copyright 2010 Wiley-Liss, Inc.
BACKGROUND: Many childhood malignancies including sarcomas, neuroblastoma, and Wilms tumor show the presence of both, active, type-1-insulin-like growth factor receptor (IGF-1R), and the autocrine production of its ligands IGF-1/IGF-2. IMC-A12 is a fully human IgG1 antibody that prevents ligand binding to the IGF-1R. PROCEDURES: IMC-A12 was evaluated against the 23 cell lines of the Pediatric Preclinical Testing Program (PPTP) in vitro panel using 96 hr exposure at concentrations ranging from 0.01 nM to 0.1 microM. IMC-A12 was tested in vivo at a dose of 1 mg/mouse administered intraperitoneally twice weekly for 6 weeks. RESULTS: In vitro, IMC-A12-induced T/C values <50% in only three cell lines, a rhabdomyosarcoma cell line (Rh41) and two Ewing sarcoma cell lines (TC-71 and CHLA-9). In vivo, IMC-A12 induced significant differences in EFS distribution compared to control in 24 of 34 (71%) evaluable solid tumor xenografts. Using the PPTP "time to event" activity measure, IMC-A12 induced intermediate (n = 13) or high (n = 1) activity in 33 xenografts evaluable for this activity measure, including 6 of 6 rhabdomyosarcoma xenografts, 3 of 5 osteosarcoma xenografts, 2 of 5 neuroblastoma xenografts, and 1 of 5 Ewing sarcoma xenografts. The only objective response observed was observed in a rhabdomyosarcoma xenograft (Rh28) that achieved a maintained complete response. CONCLUSIONS: IMC-A12 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression. IMC-A12 showed its greatest activity in vivo against the PPTP's rhabdomyosarcoma xenografts. Copyright 2010 Wiley-Liss, Inc.
Authors: Jennifer K Peterson; Chandra Tucker; Edward Favours; Pamela J Cheshire; Jeremy Creech; Catherine A Billups; Richard Smykla; Francis Y F Lee; Peter J Houghton Journal: Clin Cancer Res Date: 2005-10-01 Impact factor: 12.531
Authors: Peter J Houghton; Christopher L Morton; Chandra Tucker; Debbie Payne; Edward Favours; Claire Cole; Richard Gorlick; E Anders Kolb; Wendong Zhang; Richard Lock; Hernan Carol; Mimi Tajbakhsh; C Patrick Reynolds; John M Maris; Joshua Courtright; Stephen T Keir; Henry S Friedman; Charles Stopford; Joseph Zeidner; Jianrong Wu; Tiebin Liu; Catherine A Billups; Javed Khan; Sherry Ansher; Jian Zhang; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2007-12 Impact factor: 3.167
Authors: Yan Wang; Judith Hailey; Denise Williams; Yaolin Wang; Philip Lipari; Michael Malkowski; Xiaoying Wang; Lei Xie; Guanghua Li; Deba Saha; Wai Lam W Ling; Susan Cannon-Carlson; Robert Greenberg; Robert A Ramos; Robert Shields; Leonard Presta; Peter Brams; W Robert Bishop; Jonathan A Pachter Journal: Mol Cancer Ther Date: 2005-08 Impact factor: 6.261
Authors: Eric K Rowinsky; Hagop Youssoufian; James R Tonra; Phillip Solomon; Douglas Burtrum; Dale L Ludwig Journal: Clin Cancer Res Date: 2007-09-15 Impact factor: 12.531
Authors: Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Lock; Hernan Carol; C Patrick Reynolds; Nino Keshelava; John M Maris; Stephen T Keir; Jianrong Wu; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2008-01 Impact factor: 3.167
Authors: E Anders Kolb; Richard Gorlick; John M Maris; Stephen T Keir; Christopher L Morton; Jianrong Wu; Amy W Wozniak; Malcolm A Smith; Peter J Houghton Journal: Pediatr Blood Cancer Date: 2011-05-31 Impact factor: 3.167
Authors: Brenda Weigel; Suman Malempati; Joel M Reid; Stephan D Voss; Steven Y Cho; Helen X Chen; Mark Krailo; Doojduen Villaluna; Peter C Adamson; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2013-08-17 Impact factor: 3.167
Authors: Aaron Cooper; John van Doorninck; Lingyun Ji; Darren Russell; Marc Ladanyi; Hiroyuki Shimada; Mark Krailo; Richard B Womer; Jessie Hao-ru Hsu; Dafydd Thomas; Timothy J Triche; Richard Sposto; Elizabeth R Lawlor Journal: Clin Cancer Res Date: 2010-11-03 Impact factor: 12.531
Authors: Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Suman Malempati; Brenda J Weigel; Yueh-Yun Chi; Jing Tian; James R Anderson; David M Parham; Lisa A Teot; David A Rodeberg; Torunn I Yock; Barry L Shulkin; Sheri L Spunt; William H Meyer; Douglas S Hawkins Journal: Cancer Date: 2018-10-23 Impact factor: 6.860